Reduktion von Dihydro-cyclogeraniumsäure zu Dihydro-cyclogeraniol bzw. Dihydro-cyclocitral und Darstellung von cis-Dihydro-jonon
作者:P. Bächli、H. Schinz
DOI:10.1002/hlca.19510340422
日期:——
A. Cis- und trans-Dihydro-cyclogeraniol wurden aus den entsprechenden Dihydro-cyclogeraniumsäureestern durch Reduktion mit LiAlH4 hergestellt.
A.顺式-反式-二氢-环香叶醇,二氢-环香叶素-脲酸酯还原反应,LiAlH 4赫氏体。
Opsin-Binding Ligands, Compositions and Methods of Use
申请人:Bikam Pharmaceuticals, Inc.
公开号:US20150038574A1
公开(公告)日:2015-02-05
Compounds and compositions are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.
Opsin-binding ligands, compositions and methods of use
申请人:Bikam Pharmaceuticals, Inc.
公开号:US10040749B2
公开(公告)日:2018-08-07
Compounds and compositions are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.
OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE
申请人:Bikam Pharmaceuticals, Inc.
公开号:EP2785178A1
公开(公告)日:2014-10-08
[EN] OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE<br/>[FR] LIGANDS LIANT L'OPSINE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
申请人:BIKAM PHARMACEUTICALS INC
公开号:WO2013081642A1
公开(公告)日:2013-06-06
Compounds and compositions are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.